Regulatory
Biopharma companies working with the microbiome are running into patent obstacles due to the difficulty in using the system to protect naturally-occurring substances.
ISCT, the International Society for Cell and Gene Therapy announces its objection to linking the benefits of cellular immunotherapy, in particular Chimeric Antigen Receptor T-cell therapy, with recent market offerings for third party cryopreserving and banking of T-cells for future therapeutic use.
Myriad Genetics, Inc. announced that the AstraZeneca/Merck Phase III PROfound studydemonstrated that men with metastatic castration-resistant prostate cancer who tested positive for germline and somatic mutations in homologous recombination repair genes benefitted from treatment with Lynparza®, a novel PARP inhibitor.
Former Touch Bionics CEO joins Adapttech as company secures FDA decision for medical device that improves prosthesis fit
Epigenomics AG announced the operational achievements plus financial results for the second quarter and the first half of 2019.
Quanta Dialysis Technologies Ltd, a British medical technology company developing a personal haemodialysis system for patient use in the clinic and the home, announces that it has begun human factors testing of SC+ in the United States with Design Science, a leading specialist in medical device usability.
Conference call and webcast, August 07, 2019 at 3:00 pm CET, 9:00 am EST
MorphoSys AG announced its intention to submit a Marketing Authorization Application to the European Medicines Agency based on its phase 2 L-MIND study of tafasitamab and lenalidomide in relapsed or refractory diffuse large B cell lymphoma.
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
Oxford Immunotec Global PLC, or the Company, a global, high-growth diagnostics company, announced second quarter 2019 financial results.
PRESS RELEASES